LLY

1,076

-1.65%↓

JNJ

223.22

+0.45%↑

ABBV

212.61

-0.26%↓

UNH

377.52

-0.75%↓

MRK

115.8

-0.74%↓

LLY

1,076

-1.65%↓

JNJ

223.22

+0.45%↑

ABBV

212.61

-0.26%↓

UNH

377.52

-0.75%↓

MRK

115.8

-0.74%↓

LLY

1,076

-1.65%↓

JNJ

223.22

+0.45%↑

ABBV

212.61

-0.26%↓

UNH

377.52

-0.75%↓

MRK

115.8

-0.74%↓

LLY

1,076

-1.65%↓

JNJ

223.22

+0.45%↑

ABBV

212.61

-0.26%↓

UNH

377.52

-0.75%↓

MRK

115.8

-0.74%↓

LLY

1,076

-1.65%↓

JNJ

223.22

+0.45%↑

ABBV

212.61

-0.26%↓

UNH

377.52

-0.75%↓

MRK

115.8

-0.74%↓

Home・Aktien・Beam Therapeutics Inc

Beam Therapeutics Inc

Open

BrancheGesundheitswesen

30.04 -4.09

Buy Sell

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

29.44

Max

31.66

Schlüsselkennzahlen
By Trading Economics
Einkommen	-339M -94M
Verkäufe	-82M 32M
EPS	-0.91
Gewinnspanne	-297.177
Angestellte	522
EBITDA	-362M -102M

Empfehlungen
By TipRanks
Empfehlungen	Starkes Kaufsignal
12-Monats-Prognose	+51.56% upside

Dividenden
By Dow Jones
Nächstes Ergebnis	4. Aug. 2026

Marktstatistiken
By TradingEconomics
Marktkapitalisierung	-52M 3B
Vorheriger Eröffnungskurs	34.13
Vorheriger Schlusskurs	30.04

Nachrichtenstimmung

By Acuity

76%

24%

302 / 344 Ranking in Healthcare

Beam Therapeutics Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

1. Juni 2026, 23:48 UTC

Market Talk

Nikkei May Rise on Optimism Over AI Demand -- Market Talk

1. Juni 2026, 23:38 UTC

Akquisitionen, Fusionen, Übernahmen

Google Seeks $80 Billion for AI Buildout; Berkshire Will Buy $10 Billion Stake -- WSJ

1. Juni 2026, 23:37 UTC

Market Talk

Oil Edges Higher; Trump Seeks to Quell Israel-Hezbollah Conflict -- Market Talk

1. Juni 2026, 23:01 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

1. Juni 2026, 23:01 UTC

Market Talk

Dexus Stuck in 'Too Hard' Basket -- Market Talk

1. Juni 2026, 22:08 UTC

Akquisitionen, Fusionen, Übernahmen

Alphabet to Issue $80 Billion of Equity for AI Buildout. Berkshire to Buy $10 Billion. -- Barrons.com

1. Juni 2026, 22:01 UTC

Akquisitionen, Fusionen, Übernahmen

Alphabet to Issue $80 Billion of Equity for AI Buildout. Berkshire to Buy $10 Billion. -- Barrons.com

1. Juni 2026, 22:01 UTC

Akquisitionen, Fusionen, Übernahmen

Google Seeks to Raise $80 Billion for AI Infrastructure -- Update

1. Juni 2026, 21:55 UTC

Akquisitionen, Fusionen, Übernahmen

Greg Abel's Week Is Off to Quite a Start -- WSJ

1. Juni 2026, 21:53 UTC

Market Talk

Strong Earnings Suppress Concerns About Oil Market -- Market Talk

1. Juni 2026, 21:22 UTC

Market Talk

Akquisitionen, Fusionen, Übernahmen

Berkshire's Abel Takes Big Swing With Back-to-Back Deals -- Market Talk

1. Juni 2026, 20:50 UTC

Market Talk

Akquisitionen, Fusionen, Übernahmen

Tech, Media & Telecom Roundup: Market Talk

1. Juni 2026, 20:50 UTC

Market Talk

Health Care Roundup: Market Talk

1. Juni 2026, 20:50 UTC

Market Talk

Auto & Transport Roundup: Market Talk

1. Juni 2026, 20:46 UTC

Akquisitionen, Fusionen, Übernahmen

The Odds SpaceX Merges With Tesla Are Higher Than You Think -- Barrons.com

1. Juni 2026, 20:22 UTC

Akquisitionen, Fusionen, Übernahmen

Array Digital Infrastructure Doesn't Expect Additional Divs in 2026

1. Juni 2026, 20:21 UTC

Akquisitionen, Fusionen, Übernahmen

Array Digital Infrastructure Div Payable June 25 to Hldrs of Record June 11

1. Juni 2026, 20:21 UTC

Akquisitionen, Fusionen, Übernahmen

Array Digital Infrastructure Declares $11 Special Div

1. Juni 2026, 20:20 UTC

Akquisitionen, Fusionen, Übernahmen

Array Completes Sale of Select Spectrum Assets to Verizon for $1B

1. Juni 2026, 19:40 UTC

Market Talk

Remittances to Mexico Rise for Third Straight Month -- Market Talk

1. Juni 2026, 19:28 UTC

Market Talk

BoC Official Reiterates Need to Improve Business Investment -- Market Talk

1. Juni 2026, 19:01 UTC

Market Talk

Oil Futures Rise On Concerns About U.S.-Iran Talks -- Market Talk

1. Juni 2026, 18:58 UTC

Market Talk

U.S. Natural Gas Futures Snap 3-Session Winning Streak -- Market Talk

1. Juni 2026, 18:54 UTC

Akquisitionen, Fusionen, Übernahmen

Berkshire Stock Drops. Its Bargain-Priced Deal for Home Builder Fails to Impress Investors. -- Barrons.com

1. Juni 2026, 18:33 UTC

Market Talk

Mexican PMIs Show Sluggish Manufacturing in May -- Market Talk

1. Juni 2026, 18:32 UTC

Market Talk

Precious Metals Fall to Start June -- Market Talk

1. Juni 2026, 18:00 UTC

Akquisitionen, Fusionen, Übernahmen

Marsh McLennan Agency Completes Acquisition Of TriBridge Partners >MRSH

1. Juni 2026, 17:18 UTC

Market Talk

Global Asset Managers Accumulate Canadian Government Debt -- Market Talk

1. Juni 2026, 17:18 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

1. Juni 2026, 17:10 UTC

Market Talk

Akquisitionen, Fusionen, Übernahmen

Salesforce Estimated to Get $225M Sales Boost From Contentful -- Market Talk

Peer-Vergleich

Kursveränderung

Beam Therapeutics Inc Prognose

Kursziel

By TipRanks

51.56% Vorteil

12-Monats-Prognose

Durchschnitt 49.91 USD 51.56%

Hoch 80 USD

Tief 26 USD

Basierend auf 12 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Beam Therapeutics Inc – Dist angeboten haben.

Rating-Konsens

By TipRanks

Starkes Kaufsignal

12 ratings

Buy

Halten

Sell

Basierend auf 12 Analysten, die in den letzten 3 Monaten Aktienbewertungen für Beam Therapeutics Inc – Dist abgegeben haben.

Stimmung

By Acuity

302 / 344 Ranking in Gesundheitswesen

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

Über Beam Therapeutics Inc

Beam Therapeutics Inc., a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. It develops BEAM-101 for the treatment of sickle cell disease or beta-thalassemia; and BEAM-302, a liver-targeting LNP formulation to treat severe alpha-1 antitrypsin deficiency; BEAM-201, an anti-CD7 CAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of refractory T-cell acute lymphoblastic leukemia/T cell lymphoblastic lymphoma; and BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease 1a. The company has research collaboration agreement with Pfizer Inc., focus on in vivo base editing programs for targets rare genetic diseases of the liver, muscle, and central nervous system; Apellis Pharmaceuticals to conduct preclinical research on target specific genes within the complement system in various organs, including the eye, liver, and brain; Verve Therapeutics, Inc., for cardiovascular disease treatments; Sana Biotechnology, Inc., to research, develop, and commercialize rights to CRISPR Cas12b for cell therapy programs; and Orbital Therapeutics design RNA for the prevention, treatment or diagnosis of human disease. Beam Therapeutics Inc. was incorporated in 2017 and is based in Cambridge, Massachusetts.